The Wisconsin-based clinical-stage company’s single-replication flu vector has the potential to provide better efficacy against seasonal influenza and protection against future pandemic strains.
Based in Madison, WI, FluGen is a clinical-stage company transforming vaccine efficacy in respiratory diseases. The company’s lead candidate is M2SR--a live, single-replication, intranasal flu vaccine that has demonstrated protection against infection and illness across seven years of virus drift, and induced a durable antibody response with the potential to cover an entire flu season and beyond. [FluGen]
The company’s lead candidate is M2SR—a live, single-replication, intranasal flu vaccine based on an invention by UW Madison virologists and FluGen co-founders Yoshihiro Kawaoka, PhD, and Gabriele Neumann PhD. In an unprecedented challenge trial, M2SR demonstrated protection against infection and illness across seven years of virus drift and induced a durable antibody response with the potential to cover an entire flu season and beyond . . .
